Chloroquine Dosing Recommendations for Pediatric COVID‐19 Supported by Modeling and SimulationBrief Report Published on 2020-05-212022-10-31 Journal: Clinical Pharmacology and Therapeutics [Category] COVID-19, MERS, [키워드] adolescents and adults Adults age AUC children Chloroquine clinical trial Control coronavirus disease COVID‐19 cumulative dosage dose doses doses for children Dosing evaluate malaria modeling Patient pediatric pharmacokinetic pharmacokinetic data predicted recent regimen Simulation Support Treatment Variation was determined was tested was used WHO World Health Organization [DOI] 10.1002/cpt.1864 PMC 바로가기 [Article Type] Brief Report
Overwhelming COVID-19 Clinical Trials: Call for Prospective Meta-AnalysesCorrespondence Published on 2020-05-202022-10-05 Journal: Trends in pharmacological sciences [Category] SARS, 임상, [키워드] clinical clinical trial COVID-19 Prospective Prospective meta-analysis [DOI] 10.1016/j.tips.2020.05.002 [Article Type] Correspondence
MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and EfficacyImmunology Published on 2020-05-192022-11-01 Journal: Frontiers in Immunology [Category] COVID-19, MERS, [키워드] acute respiratory distress adaptive approved ARDS Blood cause Cell cellular characterized clinical guideline clinical trial coagulation/clotting/thrombosis coronavirus-induced disease 2019 (COVID19) COVID-19 COVID-19 patient COVID-19 patients criteria Critical Critically ill delivery disease Disseminated intravascular coagulation effective effective therapy Express expression fatality hemocompatibility testing high risk hypercoagulable immune immunomodulatory effects Importance Inflammation intensive care unit (ICU) intravascular and intravenous infusion intravenous IV infusion mesenchymal stromal cells (MSC) mitigate mode Mortality MSC MSC therapy MSCs multi-organ failure Numerous organ Patient patient population Pneumonia procoagulant procoagulant tissue factor product promote Quality Registered risk robust Safe Safety safety profile Sepsis severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) shown syndrome Therapies therapy Thromboembolism thrombotic tissue tissue factor (TF/CD142) tissue repair Treatment while [DOI] 10.3389/fimmu.2020.01091 PMC 바로가기 [Article Type] Immunology
Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs against Human Coronavirus 229E (HCoV-229E)Brief Report Published on 2020-05-172022-10-30 Journal: Molecules [Category] COVID-19, MERS, SARS, [키워드] 229E activity Antiviral antiviral activity can be used cells clinical trial Comparative Compound compounds concentrations conjugate Conjugates COVID-19 cytotoxicity determine DNA polymerase EFdA exhibited fibroblast HCoV-229E human coronavirus human coronavirus 229E inactive inhibitor interfere lung cell normal NRTIs nucleoside nucleotide prodrug other coronaviruses parent Remdesivir RNA polymerase RNA-dependent RNA polymerase SARS-CoV-2 tested Treatment were used with HIV [DOI] 10.3390/molecules25102343 PMC 바로가기 [Article Type] Brief Report
Identification of Repurposable Drugs and Adverse Drug Reactions for Various Courses of COVID-19 Based on Single-Cell RNA Sequencing DataArticle Published on 2020-05-162022-10-28 Journal: ArXiv [Category] COVID-19, [키워드] Adverse Adverse drug reaction anti-SARS-CoV-2 anti-virus drug approach candidate clinical trial Compound Coronavirus disease 2019 COVID-19 dataset Disease progression drug Drug repurposing drugs effective Efficacy evaluate FDA-approved drug Gene Expression Health highlighting identification identify impacted influenza A virus inhibitory effect library Library of Integrated Network-Based Cellular Signatures LINCS Mild reaction Replication RNA SARS-CoV-2 SARS-COV-2 infection severe COVID-19 patients signature Single-cell RNA sequencing single-stranded ssRNA Systems biology tested virus PMC 바로가기 [Article Type] Article
Deubiquitinating Enzymes in Coronaviruses and Possible Therapeutic Opportunities for COVID-19Review Published on 2020-05-152022-10-29 Journal: International Journal of Molecular Sciences [Category] COVID-19, MERS, SARS, [키워드] activity acute respiratory syndrome affecting antiviral therapy clinical trial Consensus coronavirus coronavirus disease coronavirus epidemics Coronavirus infections COVID-19 COVID-19 therapy cysteine proteases drugs DUBs enzyme evaluated expressed function host cell host’s immune response immune response IMPROVE in vitro Infection inhibitor innate immune response intrinsic ISG15 majority Modification multifunctional opportunity outbreak pandemic Papain-like protease Pathogenesis pathway patient survival Pleiotropic effects PLP PLP inhibitors polypeptides Prevent protease Protein Proteins regulate Regulatory required responsible SARS SARS-CoV2 second Spread stability target proteins therapeutic strategy treat Treatment ubiquitin Viral pneumonia viral replication [DOI] 10.3390/ijms21103492 PMC 바로가기 [Article Type] Review
The Rationale for Potential Pharmacotherapy of COVID-19Review Published on 2020-05-142022-10-28 Journal: Pharmaceuticals [Category] COVID-19, [키워드] ACE2 active against addition Antiviral Baricitinib Care cause Chloroquine clinical care Clinical management clinical trial clinical trials Clinical use Compound computational analysis Consensus coronavirus disease coronavirus epidemics Coronavirus infection coronavirus SARS-CoV-2 COVID-19 COVID-19 patient COVID-19 patients defined effective Epidemiology Evidence Favipiravir Health include increasingly Infection interferons investigated Lopinavir medication MERS-CoV Middle East molecular biology technique other disease pandemic pharmacological treatment pharmacotherapy Potential potential therapies professional Randomized rationale Remdesivir respiratory syndrome coronavirus SARS-CoV SARS-CoV-2 shown Spread Standard of care suggested tested Therapies therapy TMPRSS2 virus World Health Organization Wuhan, China [DOI] 10.3390/ph13050096 PMC 바로가기 [Article Type] Review
Oncology clinical trials in the time of COVID-19: how a pandemic can revolutionize patients’ careEditorial Published on 2020-05-142022-10-31 Journal: Future Oncology [Category] Coronavirus, MERS, SARS, [키워드] clinical trial clinical trials coronavirus COVID-19 oncology pandemic patient benefit treatment decisions [DOI] 10.2217/fon-2020-0364 PMC 바로가기 [Article Type] Editorial
Novel coronavirus (COVID-19) infection: What a doctor on the frontline needs to knowReview Article Published on 2020-05-132022-10-28 Journal: Annals of Medicine and Surgery [Category] COVID-19, [키워드] Admission Antibiotics changes Chest China Clinical practice clinical trial Computed tomography coronavirus coronavirus disease Coronavirus disease 2019 cough COVID-19 COVID-19 pandemic drugs Fever guideline healthcare Hospital admission Hydroxychloroquine include Infection intensive care Junior doctor management mild symptoms novel oxygen supplementation pandemic Patient Pneumonia provide public health crisis radiological feature Remdesivir Respiratory failure respiratory infection severe symptoms Spread Symptom the disease Treatment World Health Organisation Wuhan Wuhan, China zoonotic [DOI] 10.1016/j.amsu.2020.05.014 PMC 바로가기 [Article Type] Review Article
Can Unconventional Immunomodulatory Agents Help Alleviate COVID-19 Symptoms and Severity?Opinion/Hypothesis Published on 2020-05-132022-10-30 Journal: mSphere [Category] COVID-19, MERS, SARS, [키워드] absence acute respiratory syndrome agent Anti-inflammatory antiviral agent Can CCL2 chemokines clinical trial coronavirus COVID-19 COVID-19 symptom CXCL10 disease symptom DNA effective Effectiveness evaluate IL-1 IL-6 immune response immunomodulatory activity Immunomodulatory agent Immunomodulatory agents immunopathological induce Inflammatory Inflammatory cytokine inhibit Interferon alpha low-dose phytocannabinoids Protein respiratory infection SARS Coronavirus SARS-CoV-2 severity Th1 Th1 cytokine Th2 thimerosal Vaccine variety [DOI] 10.1128/mSphere.00288-20 PMC 바로가기 [Article Type] Opinion/Hypothesis